Company Overview
Snapshot
Founded in December 2015 by Oded Sagee, PlantEXT operates with 1-10 employees. The company has raised a total of $5.6M across three funding rounds. In October 2020, PlantEXT appointed Willy Kruh as its Chief Executive Officer.
Business overview
PlantEXT is a Health Tech & Life Sciences company focused on discovering and developing active cannabis extracts for anti-inflammatory remedies. The company's core technology involves isolating therapeutic elements at the molecular level and quantifying anti-inflammatory activity through in-vitro and ex-vivo studies. PlantEXT serves the healthcare and pharmaceuticals markets, operating within the medical cannabis, drugs discovery & development, and biologicals sectors. It is currently launching its first line of IBD medical cannabis products in Israel, with plans for international expansion and additional medical products for indications such as psoriasis, atopic dermatitis, arthritis, pain, and migraines.
Strategic signal
In October 2020, PlantEXT announced research exploring pharmaceutical cannabis as a therapy for COVID-19, specifically investigating its potential to reduce lung inflammation. This signals the company's strategic agility in applying its core cannabis research capabilities to emerging global health challenges, potentially opening new market opportunities beyond its initial focus on inflammatory conditions.
Log in to access full profile ›Company Intelligence Q&A
- What is PlantEXT's primary focus in product development?
- PlantEXT is focused on discovering and developing active cannabis extracts with a focus on anti-inflammatory remedies. The company has developed a pipeline of anti-inflammatory products supported by pre-clinical and clinical research.
- What significant leadership change occurred at PlantEXT?
- In October 2020, PlantEXT appointed Willy Kruh, former KPMG International Global Chair of Consumer and Retail, as its Chief Executive Officer.
- Has PlantEXT engaged in any strategic partnerships for product development?
- In April 2019, PlantEXT entered into a joint venture agreement with Family Secret Ltd. to develop and commercialize topical medical cannabis treatments for inflammation-related medical conditions.
- What was the outcome of the proposed transaction with BB1 Acquisition Corp.?
- In January 2020, BB1 Acquisition Corp. announced the termination of its proposed three-cornered amalgamation with PlantEXT Ltd., as the share exchange agreement between the parties had expired.
- What research collaboration has PlantEXT established?
- PlantEXT has a research agreement with the agricultural research organization Volcani Center and holds exclusive rights to commercialize the results and products worldwide.